Non-Hodgkin Lymphoma Clinical Trials
Non-Hodgkin Lymphoma clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for non-Hodgkin Lymphoma. Corterve aggregates actively recruiting Non-Hodgkin Lymphoma studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Non-Hodgkin Lymphoma studies
- Personalized NK Cell Therapy in CBTNCT02727803PHASE2M.D. Anderson Cancer CenterHouston, Texas
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaNCT03223610PHASE1, PHASE2National Cancer Institute (NCI)Bethesda, Maryland
- A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin LymphomaNCT05645107PHASE3Grifols Therapeutics LLCHuntington Park, California
- IKS03 in Patients With Advanced B Cell Non-Hodgkin LymphomasNCT05365659PHASE1Iksuda Therapeutics Ltd.Baltimore, Maryland
- Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell LymphomaNCT03011814PHASE1, PHASE2City of Hope Medical CenterDuarte, California
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell TransplantNCT07020533PHASE1City of Hope Medical CenterDuarte, California
- This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin LymphomaNCT07121946PHASE1LTZ Therapeutics, Inc.Duarte, California
- A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell MalignanciesNCT05006716PHASE1, PHASE2BeOne MedicinesBirmingham, Alabama
- Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic DiseasesNCT06013423PHASE2Fred Hutchinson Cancer CenterSeattle, Washington
- IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersNCT06119685PHASE1, PHASE2Indapta Therapeutics, INC.Los Angeles, California
- Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-CelNCT05794958PHASE1Stanford UniversityPalo Alto, California
- T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)NCT06343311PHASE1, PHASE2Estrella Biopharma, Inc.Sacramento, California
Non-Hodgkin Lymphoma trials by state
Non-Hodgkin Lymphoma trials by metro
Frequently asked questions
- How do I find recruiting Non-Hodgkin Lymphoma clinical trials?
- Corterve aggregates actively recruiting Non-Hodgkin Lymphoma studies from the public ClinicalTrials.gov registry. Browse the studies listed on this page or take a free health assessment to see trials you may qualify for based on your profile.
- Are Non-Hodgkin Lymphoma clinical trials free to join?
- Study participation is typically free — research sponsors cover the cost of the investigational treatment and study-related visits. Many trials also compensate participants for time and travel. Details vary by study.
- Who can take part in a Non-Hodgkin Lymphoma clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.